Climb Bio (CLYM) Non Operating Investment Income (2021 - 2026)
Climb Bio (CLYM) posted Non Operating Investment Income of -$278000.0 for Q1 2026, down 717.65% on a QoQ basis from -$34000.0 in Q4 2025, and down 205.7% year-over-year from $263000.0 in Q1 2025.
Climb Bio (CLYM) Non Operating Investment Income (2021 - 2026) Analysis & Trends
Climb Bio's Non Operating Investment Income history runs 6 years deep, the most recent figure standing at -$278000.0 for Q1 2026.
- Quarterly Non Operating Investment Income fell 205.7% year-over-year to -$278000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129000.0 (down 145.1% YoY) and the FY2025 annual result came in at $412000.0, up 1548.0% from the prior year.
- Non Operating Investment Income was -$278000.0 for Q1 2026 at Climb Bio, down from -$34000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $263000.0 in Q1 2023 and bottomed at -$398000.0 in Q1 2022.
- A 5-year average of $17500.0 and a median of $23500.0 in 2022 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income sank 2077.78% — and 2025, when it surged 13050.0%.
- Climb Bio's Non Operating Investment Income stood at $223000.0 in 2022, then slumped by 95.96% to $9000.0 in 2023, then sank by 2077.78% to -$178000.0 in 2024, then soared by 80.9% to -$34000.0 in 2025, then tumbled by 717.65% to -$278000.0 in 2026.
- Business Quant data shows CLYM's Non Operating Investment Income at -$278000.0 in Q1 2026, -$34000.0 in Q4 2025, and $151000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Climb Bio | 877.15 Mn | 877.15 Mn | - | -278,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -278,000.00 |
| Mar 31, 2026 | -278,000.00 |
| Dec 31, 2025 | -34,000.00 |
| Dec 31, 2025 | -34,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Jun 30, 2025 | 32,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | -178,000.00 |
| Dec 31, 2024 | -178,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | 24,000.00 |
| Sep 30, 2023 | 24,000.00 |